Technical Analysis for RXDX - Prometheus Biosciences, Inc.

Grade Last Price % Change Price Change
F 21.05 -2.50% -0.54
RXDX closed down 2.5 percent on Tuesday, July 27, 2021, on 26 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical RXDX trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.50%
Narrow Range Bar Range Contraction -2.50%
NR7 Range Contraction -2.50%
Stochastic Reached Oversold Weakness -2.50%
Wide Bands Range Expansion -2.50%
Oversold Stochastic Weakness -2.50%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.32%
Older End-of-Day Signals for RXDX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 11 hours ago
Down 3% about 13 hours ago
Down 2 % about 13 hours ago
Non-ADX 1,2,3,4 Bearish Retracement Entry about 13 hours ago
Fell Below Previous Day's Low about 13 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Prometheus Biosciences, Inc. Description

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Immunology Inflammatory Bowel Disease Tumor Necrosis Factor Inflammatory Bowel Diseases

Is RXDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 30.64
52 Week Low 16.11
Average Volume 200,653
200-Day Moving Average 0.00
50-Day Moving Average 22.81
20-Day Moving Average 23.69
10-Day Moving Average 21.56
Average True Range 1.91
ADX 14.3
+DI 19.67
-DI 19.26
Chandelier Exit (Long, 3 ATRs) 21.99
Chandelier Exit (Short, 3 ATRs) 26.20
Upper Bollinger Bands 28.30
Lower Bollinger Band 19.07
Percent B (%b) 0.21
BandWidth 38.96
MACD Line -0.59
MACD Signal Line -0.23
MACD Histogram -0.3638
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.34
Resistance 3 (R3) 22.40 22.03 22.13
Resistance 2 (R2) 22.03 21.70 22.00 22.05
Resistance 1 (R1) 21.54 21.50 21.36 21.48 21.98
Pivot Point 21.17 21.17 21.08 21.14 21.17
Support 1 (S1) 20.68 20.84 20.50 20.62 20.12
Support 2 (S2) 20.31 20.64 20.28 20.05
Support 3 (S3) 19.82 20.31 19.98
Support 4 (S4) 19.76